2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Gastrointestinal Stromal Tumors
71
Leukemia
69
Leukemia, Myeloid, Chronic-Phase
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
43
Blast Crisis
22
Neoplasms
15
Brain Neoplasms
15
Philadelphia Chromosome
14
Melanoma
13
Sarcoma
12
Neoplasm Metastasis
12
Leukemia, Myeloid, Acute
12
Leukemia, Myeloid, Accelerated Phase
12
Glioblastoma
12
Lung Neoplasms
11
Prostatic Neoplasms
10
Leukemia, Myeloid
9
Gliosarcoma
9
Glioma
8
Breast Neoplasms
8
Primary Myelofibrosis
7
Leukemia, Myelomonocytic, Chronic
7
Central Nervous System Neoplasms
7
Astrocytoma
7
Recurrence
6
Polycythemia Vera
6
Ovarian Neoplasms
6
Oligodendroglioma
6
Myeloproliferative Disorders
6
Interventions
mirdametinib
2
tipifarnib
1
talimogene laherparepvec
1
peginterferon alfa-2b
1
nilotinib
1
binimetinib
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Vincristine
1
Temozolomide
1
Talaporfin
1
Sirolimus
1
Restraint, Physical
1
Ranibizumab
1
Radiosurgery
1
Photochemotherapy
1
Neurofibromin 1
1
Mn-PyC3A
1
Imatinib Mesylate
1
Everolimus
1
Elasticity Imaging Techniques
1
Deoxycholic Acid
1
Cryotherapy
1
Celecoxib
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibroma
×
Imatinib Mesylate
×
Clear all
NCT01140360
2017-07-02
0908-09
Indiana University
Phase 1/2
Completed
21 enrolled
8 charts